• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sweetch adds American Diabetes Association exec to its advisory board

April 26, 2022 By Sean Whooley

Sweetch
[Image from Sweetch]
Chronic condition therapeutic developer Sweetch announced today that Dr. Robert A. Gabbay has joined the company as an advisor.

Gabbay currently serves as the chief scientific and medical officer at the American Diabetes Association, leading the organization’s efforts to drive discovery in diabetes research, care and prevention. He also serves as an associate professor of medicine at Harvard Medical School, having previously been CMO at Joslin Diabetes Center.

“The burdensome diabetes care regimens make people with this condition especially prone to nonadherence. For this reason, and many more, Dr. Gabbay is an exemplary fit for our advisory board,” Sweetch CEO Yoni Nevo said in a news release. “As we accelerate our growth and integration into more health and life science organizations, Dr. Gabbay’s deep understanding of such organizations and their patients will be invaluable.”

Tel Aviv-based Sweetch develops digital therapeutics and an engagement platform for chronic conditions. The company uses artificial intelligence and emotional intelligence in its clinically-validated digital therapeutics platform to move individuals to achieve their health goals through hyper-personalized recommendations at the right time, in the right tone and in real-world context.

“I am encouraged by many digital health providers incorporating AI into diabetes treatment, but platforms still lack contextual, just-in-time personalization, an absence that prevents them from fully delivering on their promises,” Gabbay said. “People with diabetes need better tools to help them navigate their diabetes every day to improve the quality of their lives. Solving these issues for people with diabetes will undoubtedly lead to better outcomes for people with chronic conditions worldwide.”

Filed Under: Big Data, Business/Financial News, Diabetes, Featured, Patient Monitoring, Technology Tagged With: Personnel, Personnel Moves, Sweetch

IN CASE YOU MISSED IT

  • Retractable Technologies declares dividends
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • West Pharmaceutical Services debuts new needle syringe system
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS